| Code | CSB-RA897523MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to UBP-1213, targeting TNFSF13B (tumor necrosis factor superfamily member 13B), also known as BAFF (B-cell activating factor) or BLyS. TNFSF13B is a cytokine that plays a crucial role in B-cell survival, maturation, and differentiation by binding to receptors including BAFF-R, TACI, and BCMA. Elevated levels of TNFSF13B have been implicated in various autoimmune disorders, including systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome, as well as in B-cell malignancies such as multiple myeloma and certain lymphomas. The dysregulation of BAFF signaling contributes to autoantibody production and aberrant B-cell proliferation.
UBP-1213 represents a therapeutic antibody designed to neutralize TNFSF13B activity, making this biosimilar a valuable tool for investigating BAFF-mediated pathways in immunological research. This antibody enables researchers to study B-cell biology, autoimmune disease mechanisms, and potential therapeutic interventions targeting the TNFSF13B axis in preclinical models and cellular systems.
There are currently no reviews for this product.